Genetic Testing for Psychiatric Medication

The short answer

Pharmacogenomic testing is a one-time genetic test, usually a cheek swab, that shows how your body is likely to process many psychiatric medications. It can guide dose choices and help avoid medications likely to cause side effects. It does not predict which medication will work. Stedfast Psychiatry offers it when the result could change your treatment.

At Stedfast Psychiatry we use pharmacogenomic results as one input to prescribing, alongside your diagnosis, history, other medications and preferences. It is most useful when one or more medications have failed or caused side effects that seemed out of proportion to the dose. It does not tell us which medication will work, and we say so plainly before ordering it.

Who it is for

The test is most useful for people who have tried one or more psychiatric medications without enough benefit, people who had strong side effects at ordinary doses, and people taking several medications where interactions matter. It can also help when a medication with a known gene-drug interaction in its FDA labeling is being considered, such as citalopram, where people who are poor CYP2C19 metabolizers have a lower maximum dose, or carbamazepine, where certain HLA gene variants raise the risk of a serious skin reaction. It is rarely needed before a first, low-dose trial of a common antidepressant, and it is never a substitute for a full psychiatric evaluation.

How it works

Most psychiatric medications are broken down in the liver by a family of enzymes called cytochrome P450. The genes that build these enzymes, especially CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2, vary from person to person. Based on those variants, the laboratory classifies you as a poor, intermediate, normal, rapid or ultrarapid metabolizer for each enzyme. A poor metabolizer of CYP2D6, for example, may build up higher blood levels of medications such as aripiprazole, atomoxetine or several tricyclic antidepressants; an ultrarapid metabolizer may clear them before they work. Some panels also report genes linked to medication response or risk, such as HLA-B and HLA-A variants tied to serious reactions to carbamazepine and related medications. The report groups medications by how strongly your genes are expected to affect them, and your provider reads it against published guidance, chiefly FDA drug labeling and the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for antidepressants.

In the GUIDED trial of 1,167 adults with depression who had not responded to at least one medication, test-guided care improved response and remission rates at week 8 compared with usual care, while the primary measure of symptom improvement did not reach statistical significance.

Source: Greden et al., Journal of Psychiatric Research, 2019

In the PRIME Care trial of 1,944 veterans with major depression, pharmacogenomic testing reduced prescribing of medications with predicted gene-drug interactions and produced a small increase in remission over 24 weeks.

Source: Oslin et al., JAMA, 2022

The FDA maintains a Table of Pharmacogenetic Associations listing gene-drug pairs with labeling or data supporting therapeutic management recommendations, including several antidepressants and antipsychotics.

Source: U.S. Food and Drug Administration

What to expect

Your provider first explains what the test can and cannot answer for you and confirms that the result could change a decision. The sample is usually a painless cheek swab. It is sent to an outside laboratory, and results typically return within one to two weeks; your provider will tell you the timeline for the laboratory used. You then review the report together at a follow-up visit, in person or by video, and decide on any medication or dose change. Your genes do not change, so the result stays valid for life. Keep a copy and share it with your primary care clinician and pharmacist, because it applies to many non-psychiatric medications as well.

Benefits

One cheek swab; the result stays valid for life
Flags medications your body is likely to clear too fast or too slowly
Supports dose decisions for medications with FDA pharmacogenomic labeling
Most useful after one or more medication trials have not worked
Reviewed with your prescriber, not handed over as a list of good and bad drugs
Applies to many non-psychiatric medications you may take later

Risks and side effects

The swab itself carries no physical risk. The real risks are about interpretation. A report can look more certain than the science behind it: many listed gene-drug links rest on modest evidence, and the FDA has cautioned that claims connecting genetic results to whether an antidepressant will work are not established. Being labeled a normal metabolizer does not mean a medication will help, and being labeled a poor metabolizer does not always rule a medication out; it may mean a lower dose. That is why we use the report alongside your history rather than in place of it. Your results are protected health information. Federal law (GINA) limits the use of genetic information by health insurers and most employers, though it does not cover life, disability or long-term care insurance.

Cost and insurance

Coverage for pharmacogenomic testing depends on your plan and the laboratory. Medicare and some commercial plans cover it for certain patients, often after at least one medication has not worked, and some plans require prior authorization. Many laboratories also offer financial assistance programs. Before the sample is collected, we confirm your coverage and tell you your expected cost, so there are no surprises. The visits to order and review the test are billed like other follow-up visits.

What the report looks like

Most reports sort medications into groups, often colored green, yellow and red, by how strongly your genes are expected to affect them. A medication in the most cautious group is not forbidden; it usually means a dose adjustment, closer monitoring or a preference for an alternative when one is equally suitable. A medication in the least cautious group is not guaranteed to work. Your provider reads the report medication by medication, against FDA labeling and CPIC guidance, and explains which findings matter for you.

Where the evidence is strongest

The strongest evidence concerns how fast medications are cleared. CPIC guidelines give dose recommendations for selective serotonin reuptake inhibitors such as citalopram, escitalopram and sertraline based on CYP2C19, and for paroxetine and fluvoxamine based on CYP2D6, as well as for tricyclic antidepressants. FDA labeling for several psychiatric medications, including citalopram, aripiprazole, atomoxetine and pimozide, includes genotype-based dosing information. HLA-B*15:02 testing is recommended before carbamazepine in people with ancestry from parts of Asia because of the risk of a severe skin reaction. Evidence for genes that claim to predict whether a medication will work, rather than how it is processed, is weaker.

How it fits with the rest of your care

Pharmacogenomic testing works best inside a careful evaluation: an accurate diagnosis, an honest account of what has been tried, at what dose and for how long, and attention to sleep, substances, thyroid and other medical factors. When several medications have failed at adequate doses and durations, the next step may be a different strategy altogether, such as psychotherapy, augmentation, Deep TMS or Spravato, rather than another medication chosen from a list. The test helps refine medication choices; it does not replace those decisions.

What we will not do

We do not order the test as a routine screen, we do not use it to label medications as right or wrong for you, and we do not change a medication that is working because of a report alone. If you already have a pharmacogenomic report from another laboratory, bring it; we can usually use it rather than repeating the test.

Frequently asked questions

Will a genetic test tell me which antidepressant will work?

No. It tells you how your body is likely to process many medications, which helps with dosing and with avoiding medications likely to cause side effects. Whether a medication relieves your symptoms depends on much more than metabolism, including the diagnosis, how long and at what dose it was tried, and other conditions. Studies show the test can modestly improve outcomes when used this way, not that it picks the right drug.

Who should consider pharmacogenomic testing?

People who have tried one or more psychiatric medications without enough benefit, people who had unusually strong side effects at ordinary doses, and people on several medications where interactions matter. It is rarely needed before a first trial of a common antidepressant at a standard starting dose. Your provider will tell you whether the result is likely to change your plan before ordering it.

How is the sample collected?

Usually with a painless cheek swab. The sample goes to an outside laboratory, and results typically return within one to two weeks. Your provider will tell you how the sample is collected and the expected timeline for the laboratory used, then review the results with you at a follow-up visit.

Does insurance cover it, and what will it cost?

Coverage depends on your plan and the laboratory. Medicare and some commercial plans cover it for certain patients, often after at least one medication has not worked, and some require prior authorization. Many laboratories offer financial assistance. We confirm your coverage and tell you your expected cost before the sample is collected.

Do I need to repeat the test?

No. Your genes do not change, so one test applies for life. Laboratories occasionally add new genes to their panels, and interpretations can be updated as research advances, so keep a copy of your report and share it with your primary care clinician and pharmacist.

Is my genetic information private?

Your results are protected health information and are kept in your medical record like any other test. The federal Genetic Information Nondiscrimination Act limits how health insurers and most employers can use genetic information. It does not apply to life, disability or long-term care insurance, which is worth knowing before any genetic test.

Where this treatment is offered

Conditions this treats

Major Depressive Disorder Treatment-Resistant Depression Generalized Anxiety Disorder Bipolar Disorder ADHD in Adults and Children Obsessive-Compulsive Disorder

If you are in crisis, call or text 988 or go to the nearest emergency room. Educational content; individual results vary. Reviewed by Dr. David Husted, board-certified psychiatrist.

Pharmacogenomic (Genetic) Testing for Psychiatric Medication